Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials
From MaRDI portal
Publication:3078908
DOI10.1111/j.0006-341X.2002.00089.xzbMath1209.62269OpenAlexW1980604813WikidataQ30679019 ScholiaQ30679019MaRDI QIDQ3078908
Ying-Kuen Cheung, Peter F. Thall
Publication date: 1 March 2011
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.0006-341x.2002.00089.x
competing risksdependent censoringhistorical dataapproximate posteriormixture of beta distributionsinterim analyses
Applications of statistics to biology and medical sciences; meta analysis (62P10) Censored data models (62N01) Bayesian inference (62F15) Medical applications (general) (92C50)
Related Items
Adaptive Randomization for Multiarm Comparative Clinical Trials Based on Joint Efficacy/Toxicity Outcomes ⋮ Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial ⋮ Risk-Group-Specific Dose Finding Based on an Average Toxicity Score ⋮ Ethical issues in oncology biostatistics ⋮ A Bayesian adaptive design for two-stage clinical trials with survival data
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Nonparametric Estimation from Incomplete Observations
- Estimation and Testing in a Two-Sample Generalized Odds-Rate Model
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- A nonidentifiability aspect of the problem of competing risks.
- Nonparametric Bayesian Estimation of Survival Curves from Incomplete Observations
- The Analysis of Failure Times in the Presence of Competing Risks
- Incorporating Toxicity Considerations Into the Design of Two-Stage Phase II Clinical Trials
- Bayesian Monitoring of Event Rates with Censored Data
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
- Bivariate Sequential Designs for Phase II Trials
